Previous BiKEs have shown success in depleting cancer cells with overexpression (e.g., HER2 over-expressing cancers) (11, 60), but it was unknown whether the technology could be used to deplete the primary cells, especially those with limited antigen expression. Here, ERBB2 is linked to cancer.